New weight loss option Phentermine Juno ER tablets launches in Australian pharmacy

Features next generation delivery system free from microplastics

Australian pharmaceutical company, Juno PC launches Phentermine Juno ER tablets into pharmacy this month, a new appetite suppressant formulation, free from indigestible sodium polystrene sulphonate beads (microplastics)1-5 and does not contain lactose, gluten & gelatin which may lower the potential for intolerance or allergies. 3-10

First introduced in 1959, phentermine remains an important and effective weight loss treatment.11 But until now, the product formula has remained relatively unchanged in Australia. This new tablet version has been co-developed by a local Australian Company “Juno PC “, in partnership with Alpex Pharma, Switzerland, to provide Australians an alternative phentermine format.1,2

Phentermine Juno ER tablets maintains its slow release profile through a patented next generation extended release delivery system without indigestible ion exchange resins formed from sodium polystyrene sulfonate – a microplastic. Microplastics are implicated in contamination of waterways and the environment. 3-5, 12-14

Phentermine Juno ER tablets are bioequivalent to Duromine® capsules, indicated in the management of excess weight and obesity. 1,2

Obesity is a progressive, chronic disease currently impacting close to 6 million Australian adults 15 and supporting effective weight management, together with the serious associated comorbidities, is a critical priority for pharmacists.

Associate Professor Nial Wheate from the University of Sydney’s School of Pharmacy believes this new phentermine sustained release tablet formulation provides an important addition to available capsule treatment options.

“The new Juno PC phentermine approach introduces a patented slow release
mechanism that moves away from indigestible microplastic beads.”

“I believe Juno PC’s new technology works in a completely different way to traditional phentermine formulations. It’s compressed hydrophobic/philic tablet appears to achieve sustained release in a new way, delivering a new bioequivalent dosage form that is environmentally friendly.”

“The tablets that Juno PC have created have demonstrated bioequivalence with Duromine based on data compiled from across four studies comparing the new formulation to standard extended release Duromine® capsules among a range of patient situations – including fasting and following food,” Associate Professor Nial Wheate added.

For more details download the full media release and brochure.